Top Markets
#1 Fake World Assets Fake World Assets +11.84%
#2 TENDIES TENDIES +6.51%
#3 Janction Janction +5.07%
#4 GoPlus Security GoPlus Security +4.45%
#5 B3 (Base) B3 (Base) +4.30%
#6 Status Status +4.24%
#7 Everything Everything +3.72%
#8 TronBank TronBank +3.26%
#9 Cross Cross +2.99%
#10 Tutorial Tutorial +2.63%
Coin of the day
Fake World Assets Fake World Assets
Ayarlar
Dil
TüRKçE
Para birimi
USD
Tema
Nicox S.A. Nicox S.A.

Nicox S.A.

COX
Hisse Senetlerindeki Sıralama #34243
Nicox S.A. is an ophthalmology enterprise operating both within France and... Nicox S.A. is an ophthalmology enterprise operating both within France and globally, focused on developing therapies to safeguard vision and enhance overall eye health. Its leading investigational drug, NCX 470, an innovative nitric oxide-donating prostaglandin analog designed to decrease intraocular pressure in individuals with open-angle glaucoma or ocular hypertension, is currently undergoing Phase 3 clinical trials. Furthermore, the company is progressing NCX 4251, a specialized fluticasone formulation, through a Phase 2b clinical trial for the management of acute exacerbations of blepharitis, as well as NCX 1728. Nicox also provides VYZULTA, a latanoprostene bunod ophthalmic solution for treating open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution to relieve ocular itching related to allergic conjunctivitis. The company, established in 1996, has its main office situated in Valbonne, France.
Hisse Fiyatı
$0.6379482
Son senkronizasyon: 2023-05-22
Piyasa Değeri
$5.98M
Değişim (1 gün)
-0.44%
Değişim (1 yıl)
0.00%
Ülke
FR
Ticaret Nicox S.A. (COX)

Kategori

Healthcare
Nicox S.A. (COX) için kazanç
2026 itibarıyla kazanç TTM: 0
Nicox S.A. şirketinin en son finansal raporlarına göre, mevcut kazancı 0'dir. 2026 yılında şirket 0 kazanç elde etti, bu 2026 yılındaki 0 kazanca göre önceki yıla eşit. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Nicox S.A. için kazanç geçmişi 2026 - 2026
Her yılın sonundaki kazanç
Yıl Kazanç Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için kazanç
Şirket Kazanç Kazanç Farkı Ülke
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE